SAN DIEGO and SUZHOU, China and SHANGHAI, China, July 31, 2023 (GLOBE NEWSWIRE) -- Gracell Biotechnologies Inc. (NASDAQ: GRCL) (“Gracell”), a global clinical-stage biopharmaceutical company dedicated to developing innovative and highly efficacious cell therapies for the treatment of cancer and autoimmune diseases, today announced that it plans to release unaudited financial results for the second quarter ended June 30, 2023 and provide an update on recent developments prior to the open of the U.S. financial markets on Monday, August 14, 2023. The management team will host a live audio webcast and conference call at 8:00 AM Eastern Time.
Conference call and webcast details:
Monday, August 14, 2023 @ 8:00am ET
Investor domestic dial-in: (800) 715-9871
Investor international dial-in: (646) 307-1963
Conference ID: 2527305
Live webcast link: https://ir.gracellbio.com/news-events/events-and-presentations
A replay of the webcast will be available on ir.gracellbio.com shortly after the conclusion of the event for 90 days.
About Gracell
Gracell Biotechnologies Inc. ("Gracell") is a global clinical-stage biopharmaceutical company dedicated to discovering and developing breakthrough cell therapies. Leveraging its pioneering FasTCAR and TruUCAR technology platforms and SMART CART™ technology module, Gracell is developing a rich clinical-stage pipeline of multiple autologous and allogeneic product candidates with the potential to overcome major industry challenges that persist with conventional CAR-T therapies, including lengthy manufacturing time, suboptimal cell quality, high therapy cost and lack of effective CAR-T therapies for solid tumors. For more information on Gracell, please visit http://www.gracellbio.com/. Follow @GracellBio on LinkedIn.
Media contacts Marvin Tang marvin.tang@gracellbio.com Jessica Laub jessica.laub@westwicke.com Investor contacts Gracie Tong gracie.tong@gracellbio.com Stephanie Carrington stephanie.carrington@westwicke.com
